Comparative Effects of Guanidinoacetic Acid (GAA) vs. Creatine in Older Adults

As we age, maintaining muscle mass and strength becomes a critical component of healthy longevity. While creatine supplementation is a well-established strategy to combat age-related muscle decline—particularly when paired with resistance training—its benefits in the absence of structured exercise are less consistent. This has led researchers to explore alternative interventions, such as guanidinoacetic acid (GAA)¹. GAA is the direct precursor to creatine in the body. Because it utilizes different transport mechanisms, it may bypass some of the age-related limitations in creatine synthesis and uptake. A recent exploratory pilot trial set out to directly compare the effects of GAA and creatine on muscle strength, body composition, and protein metabolism in older adults.

Key Takeaways

• GAA edged ahead of creatine on grip strength, but the result is borderline: Handgrip strength rose significantly in the GAA group (p=0.01) and not in the creatine group, and the between-group effect was large (Hedges' g² = 0.91). Its 95% confidence interval ran from 0.00 to 1.81 — the lower bound sits exactly on "no difference at all."
• Body composition improved within the GAA group: GAA was associated with within-group increases in fat-free mass, body cell mass, muscle mass, and total body water, with no comparable changes in the creatine group.
• Both supplements altered protein metabolism: Both GAA and creatine reduced circulating levels of myostatin³, a protein that inhibits muscle growth, though GAA produced a greater suppression.

The Study Design

This randomized, double-blind, exploratory pilot trial recruited 25 apparently healthy adults aged 65 and older. Participants were randomly assigned to receive either 2.0 grams per day of GAA or an equimolar⁴ dose of creatine monohydrate for eight weeks — matched on a per-molecule basis, that works out to roughly 2.5 grams of creatine monohydrate per day.

Notably, the trial did not include a structured exercise or resistance training program, aiming to isolate the physiological effects of the supplements themselves. Researchers measured handgrip strength, fluid and body composition (via multifrequency bioelectrical impedance analysis), and a panel of circulating biomarkers: myostatin, insulin-like growth factor-1 (IGF-1), mammalian target of rapamycin, total homocysteine, albumin, and total protein. Measurements were taken at baseline and follow-up, with intervention effects evaluated by repeated-measures ANOVA and between-group differences expressed as Hedges' g with 95% confidence intervals. Twenty-one participants completed the full eight-week intervention — eleven on GAA and ten on creatine.

The Findings

After eight weeks, handgrip strength had increased significantly in the GAA group (p=0.01) but not in the creatine group, with a significant time-by-treatment interaction (p=0.04). The between-group effect size was large, favoring GAA (Hedges' g = 0.91), but its 95% confidence interval ran from 0.00 to 1.81. That lower bound is the number to hold onto: the data are compatible with GAA being substantially better than creatine, and equally compatible with the two being identical.

GAA supplementation also produced within-group increases in fat-free mass, body cell mass, muscle mass, and total body water, while the creatine group did not show comparable changes. Effect sizes generally favored GAA for strength, muscle-related indices, and hydration compartments, though the authors note that confidence intervals were wide throughout.

Biomarker analysis revealed that both supplements reduced circulating myostatin, with the suppression more pronounced in the GAA group. Creatine supplementation produced a modest reduction in serum albumin that remained within physiological reference ranges. One planned line of investigation did not survive contact with the assay: serum IGF-1 was below the detection limit in most participants, so the growth hormone/IGF-1 axis could not be evaluated at all. Compliance exceeded 97% in both groups, and no adverse events were reported.

Analyzing the Study: Strengths & Limitations

Strengths and Reputability

A major strength of this study is its randomized, double-blind design, providing a head-to-head comparison between creatine and its immediate metabolic precursor that had not previously been run. The authors report effect sizes with confidence intervals rather than p-values alone, which is what makes the imprecision in their own results visible to a reader. Compliance rates were remarkably high, suggesting that both supplements are well-tolerated in older populations at these steady dosages.

Limitations

As an exploratory pilot trial, the sample is exceptionally small: 21 completers split into arms of eleven and ten. That is the origin of the wide confidence intervals, and it is why the headline strength result cannot exclude zero difference.

The creatine comparator deserves scrutiny. Dosing it equimolar to GAA puts it at roughly 2.5 g/day, below the 3-5 g/day maintenance range typically recommended for adults and below the floor our calculator uses. A null result in an arm that may simply be underdosed is weak evidence that creatine does not work here — particularly the absence of any change in total body water, which is one of creatine's most reliably replicated short-term effects and would ordinarily be expected to appear.

Several measured biomarkers go unreported in the abstract, including total homocysteine — the one most relevant to GAA's safety profile, since GAA supplementation is known to raise it. The IGF-1 assay failed outright. The abstract also lacks demographic or geographic detail about the cohort, limiting our understanding of exactly who these findings generalize to. No formal trial registration was found, the analysis covers completers rather than all 25 randomized participants, and the lack of a structured exercise arm makes it difficult to say how either supplement would perform alongside standard sarcopenia⁵ exercise protocols.

Conflicts of Interest

PubMed carries no conflict-of-interest statement for this record. Readers should consult the full text of the article to verify if any funding sources or commercial relationships were declared by the authors.

References

1. Todorovic N, Nedeljkovic D, Korovljev D, et al. Comparative Effects of Guanidinoacetic Acid and Creatine on Body Composition, Muscle Strength, and Protein Metabolism Biomarkers in Older Adults: A Randomized Exploratory Pilot Trial. Journal of nutritional science and vitaminology. DOI: 10.3177/jnsv.72.284

Glossary

1. Guanidinoacetic acid (GAA): A naturally occurring compound that serves as the direct metabolic precursor to creatine in the human body. ↩

2. Hedges' g: A standardised measure of how far apart two groups are, in standard deviations. Roughly, 0.2 is small, 0.5 medium and 0.8 large — but the confidence interval around it matters as much as the number itself. ↩

3. Myostatin: A protein produced by muscle cells that acts as a negative regulator, inhibiting muscle growth and differentiation. ↩

4. Equimolar: A dose containing the same number of molecules (moles) as a comparator substance, ensuring a mathematically equivalent biological comparison. ↩

5. Sarcopenia: The age-related, involuntary loss of skeletal muscle mass, strength, and physical function. ↩